Forsyth A
School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand. Electronic address: a.forsyth@auckland.ac.nz.
ArticleLSD
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial.
ArticleLSD
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
ArticleLSD
LSD microdosing in major depressive disorder: results from an open-label trial.
ArticlePsychedelics
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.
ArticleLSD
Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures.
PreprintPsilocybin
Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
PreprintPsilocybin
Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
PreprintPsilocybin
Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
PreprintPsilocybin
Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
ArticleLSD
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.
ArticleLSD
LSD increases sleep duration the night after microdosing.
ArticleLSD
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).
ArticleLSD
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
ArticlePsilocybin
Blinding and expectancy confounds in psychedelic randomized controlled trials.
PreprintPsilocybin